Prevail InfoWorks

This inspiring article from Pfizer follows a patient named Eric through his clinical trial journey. For those looking to learn more about the clinical trial process, this is a great resource. “From the thousands of patients who volunteer each year to the scientists, clinicians, and principal investigators (PIs), each individual who contributes to a trial helps to bring about life-changing treatments and advances our knowledge of diseases.” #ClinicalTrials #Patients #Safety #Discovery https://lnkd.in/eUQEb2bn

Today, we honor the courage and determination of those who fought for our independence and continue to protect our liberties. Let's take a moment to appreciate the vibrant communities that make up this great country. Whether you're enjoying a barbecue with family, watching fireworks with friends, or simply taking a day to relax, let's remember the spirit of togetherness that the 4th of July embodies. At Prevail InfoWorks, we are grateful for the opportunities that freedom provides, and we are committed to contributing positively to our society. Here's to a day filled with joy, reflection, and gratitude. Wishing everyone a safe and spectacular Independence Day from all of us at Prevail, headquartered in historic Philadelphia where the Declaration of Independence and the Constitution were signed all the way back in 1776 and 1787. #FourthOfJuly #IndependenceDay #CelebrateFreedom #Unity #Resilience #Philadelphia #Fireworks #RedWhiteandBlue 

New FDA Guidance Unveiled: Blueprint for Breaking Barriers Big and exciting clinical trial update: The FDA has recently issued its draft guidance on clinical trial diversity, detailing requirements for racial and ethnic diversity action plans. This comprehensive document outlines how to format and submit these plans, emphasizing recruitment goals aligned with disease prevalence. Companies are expected to set recruitment goals for various racial groups, categorized by age and gender, and to explain their rationale and strategies for achieving these goals. This initiative aims to improve representation in clinical trials and enhance the validity of safety and efficacy studies. In what ways do you think the FDA's new draft guidance on clinical trial diversity will influence the development and approval processes of medical products in the future? How can companies adapt their recruitment strategies to align with the FDA's new guidelines? “Participants in clinical trials should be representative of the patients who will use the medical products,” says Robert Califf, the FDA commissioner. “The agency’s draft guidance is an important step—and one of many ongoing efforts—to address the participation of underrepresented populations in clinical trials to help improve the data we have about patients who will use the medical products if approved.” Read more in the article in the comment below. #FDA #ClinicalTrials #DiversityInResearch #HealthcareEquity #MedicalResearch #FDAguidance #InclusiveTrials #PatientRepresentation #HealthcareDiversity #ResearchDiversity #TrialRecruitment

National HIV Testing Day - June 27th Today, we come together to acknowledge the power of knowledge, the strength of community, and the importance of love and care for ourselves and those around us. National HIV Testing Day is not just a date on the calendar; it's a heartfelt reminder to protect our health and the health of our loved ones.  Let’s stand together in support and compassion. By encouraging each other to get tested, we are building a community where health and love prevail.  Have you or someone you know taken the step to get tested? How has this act of self-care impacted your life? Share your experiences and thoughts below. Let’s inspire and support one another. https://lnkd.in/gCwXFDs #HIVTestingDay #HealthAwareness #StopHIVTogether #PreventHIV #CommunityHealth #GetTested #HIVAwareness #LoveAndCare 

AI to the Rescue: ChatGPT Streamlines Clinical Trials (and It's Cheaper Than a Cup of Coffee!) Researchers at Mass General Brigham discovered that AI software like ChatGPT can expedite the screening of patients for clinical trials, though they advise caution and additional safeguards. Using OpenAI’s GPT-4 through Microsoft’s Azure, the AI accurately identified eligible heart failure patients for the COPILOT-HF trial. For context, the COPILOT-HF trial seeks to determine if a virtual clinic approach can effectively guide more patients with heart failure onto guideline-recommended medication regimens remotely. The AI program was between 97.9% and 100% accurate, compared to an expert clinician’s conclusion. This method also proved cost-effective, averaging just 11 cents per patient compared to traditional manual reviews. Although not completely perfect as of now, how do you see AI transforming the future of clinical trial screening and patient care? Given its potential for high accuracy and cost-effectiveness, what could this mean for biotech and pharma companies, big and small? “We saw that large language models hold the potential to fundamentally improve clinical trial screening,” said co-senior author Sandy Aronson, executive director of IT and AI solutions for Mass General Brigham Personalized Medicine. “Now the difficult work begins to determine how to integrate this capability into real-world trial workflows in a manner that simultaneously delivers improved effectiveness, safety and equity.”­­­ This integration is a specialty of Prevail InfoWorks. Think correlating clinical data with workflows and processes for the highest quality data; think Prevail InfoWorks. Read more in the article in the comment below. #AIinHealthcare #ClinicalTrials #HealthcareInnovation #AIResearch #MassGeneralBrigham #OpenAI #ChatGPT #HeartFailure #VirtualClinics #MedicalAI #FutureOfMedicine #HealthTech #Biotech #Pharma #CostEffectiveCare #PatientCare #AIinMedicine #HealthcareAI #DigitalHealth #HealthEquity #MedicalResearch

Day One's $1.2B Deal: A New Hope for Solid Tumor Treatment Day One Biopharmaceuticals has just announced a monumental deal with MabCare Therapeutics, securing exclusive licensing rights for the innovative antibody drug conjugate (ADC), DAY301. This deal, valued at up to $1.2 billion, marks a significant step forward in the fight against solid tumors in both adults and children. Key Highlights:  Upfront Payment: Day One has paid $55 million for development and commercialization rights to DAY301, excluding the Greater China area.  Milestone Payments & Royalties: MabCare stands to gain an additional $1.15 billion in development and commercial milestones, plus single-digit royalties.  Targeted Cancers: DAY301 targets protein-tyrosine kinase 7 (PTK7), overexpressed in esophageal, ovarian, lung, and endometrial cancers in adults, as well as neuroblastoma, rhabdomyosarcoma, and osteosarcoma in children.  Regulatory Milestone: DAY301 received investigational new drug clearance from the FDA in April, with phase 1 dosing expected to begin by late 2024 or early 2025. “We believe the linker-payload technology embodied in DAY301 will overcome the limitations of earlier PTK7-targeted ADCs, giving us a potential first-in-class drug against a clinically validated target,” Samuel Blackman, M.D., Ph.D., Day One co-founder and head of R&D said. This collaboration epitomizes the relentless drive for medical innovation. Share your thoughts about this extraordinary progress. Read more in the article in the comment below. #Biopharma #Innovation #Cancer #ADCTherapy #Healthcare #Medical #ClinicalTrials #Oncology

Fueling Biotech's Next Frontier: J.P. Morgan's $500M Fund to Drive Innovation and Mentorship   Exciting biotech news from some “deep pocket” folks: J.P. Morgan Private Capital has closed its inaugural life sciences fund, raising over $500 million to invest in a diverse array of private biotechs and support existing portfolio companies. Dubbed the "270 Life Sciences Private Capital Fund I," the fund was raised in just over a year under the leadership of Stephen Squinto, Ph.D, Chief Investment Officer of J.P. Morgan Asset Management. This capital will fuel innovations across cardiometabolic disease, oncology, immunology, genetic medicines, and other therapeutic indications. Their mission goes beyond funding; they aim to mentor the next generation of biotech founders and executives as the industry evolves. Which of the disease states would you like to see get funding from J.P. Morgan? Do you think getting an investment from J.P. Morgan is a form of validation for biotechs and bodes well for a potential pharma partnership? “As the biotechnology industry enters the next era of scientific discovery, we strive to become a partner of choice for world-class researchers and entrepreneurs," says Gaurav Gupta, M.D., Managing Partner of J.P. Morgan Life Sciences Private Capital. Read more in the article in the comment below. #BiotechInnovation #LifeSciences #JPMorgan #Investment #BiotechFunding #NextGenBiotech #ScientificDiscovery #FutureOfBiotech #ResearchAndDevelopment #BiotechStartups #MedicalAdvancements #TherapeuticInnovation #PrivateCapital #InnovativeHealthcare

Transforming Eye Care: Oculis Advances Precision Medicine for Dry Eye Disease Oculis is advancing it’s precision medicine approach for treating dry eye disease with plans for a phase 3 study of its anti-TNFα eye drop, licaminlimab (OCS-02). Recent phase 2b results showed promising treatment effects, especially in patients with a specific TNFR1-related genotype. This innovative approach could revolutionize ophthalmology by tailoring treatments to individual genetic profiles. What are your thoughts on this advancement? Oculis CEO Riad SHERIF, M.D., said in a statement that the precision medicine approach could “transform the way we develop drugs and treat patients in ophthalmology.” Read more in the article in the comment below. #Biotech #PrecisionMedicine #Ophthalmology #ClinicalTrials #DryEyeDisease #Innovation #Healthcare

Itch Relief and So Much More: Gilead’s $4.3b Seladelpar Breakthrough in Liver Health Exciting progress from Gilead Sciences: data on their $4.3 billion liver disease prospect, seladelpar, shows sustained improvements over two years of treatment. This PPAR-delta agonist, acquired from CymaBay Therapeutics, has demonstrated significant results in patients with primary biliary cholangitis (PBC). After 24 months on seladelpar, 70% of trial participants met liver health markers, and ALP levels normalized in 42% of the participants during the two-year time frame. Seladelpar has additionally shown a significant reduction in pruritus (itching), addressing a crucial unmet need in PBC management. With all these exciting findings from Gilead, we look forward to the FDA's decision by mid-August. What impact could these findings have on the future of liver disease research and treatments? Could other liver conditions potentially benefit from the advancements made with seladelpar if it gets FDA approval? “This keeps you up at night. It impacts mental health. It impacts how you work. Basically, you want to scratch your skin off. There's a real opportunity here to make a difference here with seladelpar,” says Johanna Mercier, Chief Commercial Officer at Gilead. Read more in the article in the comment below. https://lnkd.in/e79T9JHZ #Gilead #HealthcareInnovation #LiverHealth #LiverDisease #PBC #PBCManagement #MedicalBreakthrough #ItchRelief #ChronicConditions #HealthcareAdvancements #FDAReview #Biopharma

Arrowhead's Plozasiran Hits the Mark in Phase 2 Hyperlipidemia Trial Arrowhead Pharmaceuticals' cholesterol disorder drug, plozasiran, showed promising results in a phase 2 trial, significantly lowering key lipoproteins linked to cardiovascular disease. The MUIR study revealed impressive triglyceride reductions of up to 62%, with most patients achieving normalized levels. Plozasiran, an RNA interference therapy, targets apolipoprotein C-III (APOC3), and boasts a robust safety profile. Analysts predict it could reach $707 million in sales by 2032, marking a major advancement in heart disease treatment. What are your thoughts on this remarkable development in cardiovascular health? Read more in the article in the comment below. #CardiovascularHealth #Pharmaceuticals #Innovation #ClinicalTrials #HeartDisease #Healthcare #Biotech #ArrowheadPharmaceuticals